Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.51 |
| ▸ | FEN1 | P39748 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | TLR4 | O00206 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6157761 | 1.00 | AKR1C3 (0.57) | AKR1C3HDAC8ERCC5FEN1SMN1; SMN2 | |
| SCHEMBL6156757 | 1.00 | AKR1C3 (0.57) | AKR1C3HDAC8ERCC5FEN1SMN1; SMN2 | |
| SCHEMBL7837384 | 0.84 | AKR1C3 (0.64) | AKR1C3HDAC8ERCC5FEN1SMN1; SMN2 | |
| SCHEMBL7837381 | 0.84 | AKR1C3 (0.64) | AKR1C3HDAC8ERCC5FEN1SMN1; SMN2 | |
| SCHEMBL6025444 | 0.82 | GAA (0.57) | SMN1; SMN2ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL6157370 | 0.82 | GAA (0.57) | SMN1; SMN2ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL6025442 | 0.82 | GAA (0.57) | SMN1; SMN2ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL28534850 | 0.79 | AKR1C3 (0.60) | AKR1C3HDAC8ERCC5FEN1SMN1; SMN2 | |
| SCHEMBL521860 | 0.78 | AKR1C3 (0.68) | AKR1C3HDAC8ERCC5FEN1SMN1; SMN2 | |
| SCHEMBL8301449 | 0.75 | CTNNB1 (0.53) | SMN1; SMN2ALDH1A1LMNARAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924300-B2 | Oxyiminoalkanoic acid derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| EP-1077957-B1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-08-04 | — | — | EP | disclosed |
| EP-1428531-A1 | Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-20030186985-A1 | Oxyiminoalkanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| US-6495581-B1 | DRUG FOR TREATING DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE, ARTERIAL SCLEROSIS AND IMPROVING INSULIN RESISTANCE, INFLAMMATORY DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| US-6251926-B1 | OXYIMINOALKANOIC ACID DERIVATIVES HAVING HYPOGLYCEMIC EFFECT AND HYPOLIPIDEMIC EFFECT, IS USEFUL FOR TREATMENT OF DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE INFLAMMATORY DISEASE AND ARTERIOSCLEROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-1077957-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058510-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186985-A1 | Oxyiminoalkanoic acid derivatives | GPR119, IRS1, CPT1A | AKR1C3 656/4885HDAC8 1219/4885ERCC5 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.